{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0066","value":"0.005"},{"groupId":"OG001","spread":"0.0046","value":"0.016"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"243"},{"groupId":"OG001","value":"477"}],"units":"Participants"}],"description":"The EQ-5D-5L is a well-validated general preference-based, health-related QoL instrument. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).","dispersionType":"Standard Error","groups":[{"description":"Participants received placebo matching niraparib 300 milligram (mg) (3×100 mg capsules) (fixed dose) once daily (QD) orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received placebo based upon the participant's Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3×100 mg capsules for participants with a Baseline body weight \\>=77 kilogram \\[kg\\] and Baseline platelet count \\>=150,000 per microliter \\[μL\\]) or 200 mg (2×100 mg capsules for participants with a Baseline body weight \\<77 kg or Baseline platelet count \\<150,000 per μL).","id":"OG000","title":"Placebo"},{"description":"Participants received niraparib 300 mg (3×100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant's Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3×100 mg capsules for participants with a Baseline body weight \\>=77 kg and Baseline platelet count \\>=150,000 per μL) or 200 mg (2×100 mg capsules for participants with a Baseline body weight \\<77 kg or Baseline platelet count \\<150,000 per μL).","id":"OG001","title":"Niraparib"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"ITT Population. Only those participants with data available at the specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1, Pre-dose) and Up to Week 24","title":"Change From Baseline in PRO: European Quality of Life Scale, 5-dimensions, 5-levels of Severity (EQ-5D-5L) Utility Score","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}